Compare SKIL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKIL | ATNM |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | 2247 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 33.9M |
| IPO Year | N/A | 2013 |
| Metric | SKIL | ATNM |
|---|---|---|
| Price | $6.25 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 55.6K | ★ 105.9K |
| Earning Date | 04-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | $0.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $3.43 | $0.95 |
| 52 Week High | $18.45 | $1.89 |
| Indicator | SKIL | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 36.75 |
| Support Level | $3.63 | $0.99 |
| Resistance Level | $8.48 | $1.27 |
| Average True Range (ATR) | 0.64 | 0.07 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 12.04 | 7.11 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.